Bevacizumab and irinotecan for glioblastoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1442-200x|57|1|169-171

ISSN： 1328-8067

Source： PEDIATRICS INTERNATIONAL, Vol.57, Iss.1, 2015-02, pp. : 169-171

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 118-128

Karger

Access to resources Recommend Favorite

Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 61, Iss. 4, 2014-04 ,pp. : 756-759

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 997-1007

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab‐induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

By  

CANCER, Vol. 121, Iss. 9, 2015-05 ,pp. : 1456-1462

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab plus Irinotecan-, Fluorouracil-, and Leucovorin-Based Chemotherapy with Concomitant HAART in an HIV-Positive Patient with Metastatic Colorectal Cancer

By  

Oncology Research and Treatment, Vol. 31, Iss. 7, 2008-06 ,pp. : 394-397

Karger

Access to resources Recommend Favorite